CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

瑞士楚格和波士顿 - 目前股价为$39.69，市值33.9亿美元的CRISPR Therapeutics (NASDAQ:CRSP)宣布了其2025年战略重点，专注于继续推出其基因药物CASGEVY®以及几个关键开发项目的更新。公司以强劲的资产负债表开始新的一年，拥有约19亿美元的现金、现金等价物和可销售证券。

在生物科技公司面临挑战的一年里，CRISPR Therapeutics AG的股票在更广泛的市场下跌中跌至52周低点，触及38.2美元。根据 InvestingPro 的数据，该公司保持"良好"的整体财务健康评分，其资产负债表显示现金多于债务，表现尤为强劲。这家以基因编辑开创性工作而闻名的公司，过去一年股价大幅回落38.23%。这一下跌反映了投资者对监管障碍、临床试验进度以及基因编辑疗法盈利能力的 ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...